Cai-based systems and methods for the localized treatment of uveitis

Abstract

This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid.

1 . A method of treating uveitis in a patient comprising administering to the patient a sustained-release system comprising a pharmaceutically effective amount of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) (CAI). 
     
     
         2 . The method of  claim 1 , wherein the sustained-release system comprises a polymer. 
     
     
         3 . The method of  claim 2 , wherein the polymer degrades over time. 
     
     
         4 . The method of  claim 3 , wherein the polymer comprises polylactic-coglycolic acid (PLGA). 
     
     
         5 . The method of  claim 1 , wherein the sustained release system comprises a non-erodible intravetreal implant. 
     
     
         6 . The method of  claim 1 , wherein the uveitis is posterior infectious uveitis. 
     
     
         7 . The method of  claim 6 , wherein the posterior infectious uveitis is caused by toxoplasmosis,  toxocara  or visceral larva migrans. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein CAI is a sonicated microparticle or in a molecular complex in formulation with hydroxypropyl β-cyclodextrin. 
     
     
         12 . A method of treating posterior infectious uveitis in a patient comprising administering a sustained-release system comprising a pharmaceutically effective amount of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and a steroid to a patient. 
     
     
         13 . The method of  claim 12 , wherein the steroid is a glucocorticoid or fluocinolone acetonide. 
     
     
         14 . The method of  claim 12 , wherein the sustained-release system comprises a polymer. 
     
     
         15 . The method of  claim 14 , wherein the polymer comprises polylactic-coglycolic acid (PLGA). 
     
     
         16 . The method of  claim 12 , wherein the steroid comprises dexamethasone. 
     
     
         17 . The method of  claim 12 , wherein the sustained-release system further comprises an anti-inflammatory agent and/or an anti-bacterial agent. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 12 , wherein CAI is a sonicated microparticle or in a molecular complex in formulation with hydroxypropyl β-cyclodextrin. 
     
     
         20 . The method of  claim 12 , wherein the sustained release system comprises a non-erodible intravetreal implant. 
     
     
         21 . The method of  claim 12 , wherein the posterior infectious uveitis is caused by toxoplasmosis,  toxocara  or visceral larva migrans. 
     
     
         22 . A sustained-release system comprising a pharmaceutically effective amount of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and a steriod, wherein CAI is a sonicated microparticle or in a molecular complex in formulation with hydroxypropyl β-cyclodextrin, and wherein the sustained-release system comprises a non-erodible intravitreal implant or a polymer. 
     
     
         23 . The sustained release system of  claim 22 , wherein the steroid is a glucocorticoid or fluocinolone acetonide. 
     
     
         24 . The sustained release system of  claim 22 , wherein the polymer comprises polylactic-coglycolic acid (PLGA).